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A B S T R A C T
Mutations in LZTR1, already known to be causal in familial schwannomatosis type 2, have been recently in-
volved in a small proportion of patients with autosomal dominant and autosomal recessive Noonan syndrome.
LZTR1 is also a driver gene in non syndromal glioblastoma. We report a 26-year-old patient with typical Noonan
syndrome, and the dominantly transmitted c.850C > T (p.(Arg284Cys)) variant in LZTR1. An oligoastrocytoma
was diagnosed in the patient at the age of 22 years; recurrence of the tumor occurred at age 26, as a gang-
lioblastoma. The patient had been transiently treated with growth hormone between ages 15 and 17.
Considering the implication of LZTR1 in sporadic tumors of the nervous system, we hypothesize that gliomas are
a possible complication of LZTR1-related Noonan syndrome. This report also supports a possible link between
occurrence of a cerebral tumor in Noonan syndrome and a previous treatment with growth hormone.
1. Introduction
LZTR1 (Leucine-zipper-like transcription regulator 1) is a tumor
suppressor gene located on 22q11.2, within the 3 Mb region that is most
commonly deleted in DiGeorge syndrome, close to NF2 and SMARCB1
(which are not located in the common DiGeorge deletion). Although its
role in cell physiology remains unclear, LZTR1 is necessary for reg-
ulation of the normal cell cycle. LZTR1 is a highly conserved gene that
contains 6 KELCH- and 2 BTB/POZ functional domains. LZTR1 is an
adaptor of the cullin 3-containing E3 ubiquitin ligase complex. It lo-
calizes to the Golgi complex. LZTR1 acts as a tumor suppressor gene:
somatic LOF mutations in LZTR1 occur in 22% of glioblastomas (high-
grade astrocytic neoplasms) (Frattini et al., 2013). These authors
showed that inactivation of LZTR1 drives self-renewal and growth of
glioma spheres.
Constitutional LZTR1 loss of function variants causes schwanno-
matosis type 2 (Piotrowski et al., 2014). Schwannomatosis is an in-
completely penetrant dominant disorder clinically defined by the pre-
sence of multiple, usually painful spinal, subcutaneous and peripheral
nerve schwannomas (including vestibular schwannomas) and rarely
meningioma. Schwannomas are nerve sheath tumor composed of
Schwann cells, the major neuroglial component of the peripheral ner-
vous system. They are usually benign and slowing growing, although
malignant degeneration in neurofibrosarcoma can occur. The molecular
signature of schwannomatosis tumors is biallelic inactivation of NF2
(by mutation and/or 22q deletion) (Ostrow et al., 2017; Plotkin et al.,
2013). Whereas SMARCB1 hypomorphic mutations represents the most
common cause of familial schwannomatosis, being mutated in 50% of
pedigrees and 10% of the sporadic cases (Hulsebos et al., 2007; Kehrer-
Sawatzki et al., 2017), constitutional mutations of LZTR1 are identified
in about 40% of familial and 30% of sporadic patients without mutation
in SMARCB1 (Louvrier et al., 2018; Paganini et al., 2015; Piotrowski
et al., 2014). Schwannomatosis-associated LZTR1 variants are spread in
all exons. All reported variants are either protein-truncating or missense
predicted to be deleterious (Kehrer-Sawatzki et al., 2017).
Noonan syndrome (NS) is a genetically heterogeneous disorder
clinically defined by a variable association of short stature, congenital
heart defect and/or cardiomyopathy, a characteristic craniofacial ap-
pearance and benign or malignant proliferative disorders, including
childhood leukemia and solid tumors of childhood onset. Most genetic
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forms of NS show a demonstrable dysregulation of the RAS/MAPK
pathway leading to a sustained or excessive activation of ERK (which
defines the RASopathies), with mutations in genes involved upstream in
the RAS/MAPK cascade or its regulation. Mutations in LZTR1 have
recently been shown to be another cause of NS (Yamamoto et al., 2015).
These authors reported 5 unrelated families with LZTR1-related NS and,
a posteriori, two NS patients screened by WES, but in which the variant
was discarded in the original publication (Chen et al., 2014). The pa-
tients with LZTR1-related NS had the typical NS facial dysmorphism
and cardiac abnormalities, short stature, ectodermal involvement,
coagulation abnormalities, and cognitive disabilities. Their mutations
were all missenses and occurred in the KELCH domains of LZTR1. In
silico analysis predicted pathogenicity, but functional studies of the
variants were not performed. Inheritance of LZTR1-linked NS was
suggested to be autosomal dominant in the first reports (Chen et al.,
2014; Shamseldin et al., 2017; Yamamoto et al., 2015) Recently auto-
somal recessive inheritance of LZTR1-linked NS was demonstrated in
twelve families, with mutations ranging throughout the protein, with
association of missense, nonsense and splicing variants (Johnston et al.,
2018). In recessive pedigrees, some heterozygous parents nevertheless
show mild signs of NS, indicating incomplete penetrance of LZTR1 at
heterozygous state (Johnston et al., 2018). So far, variants associated
with the dominant form of LZTR1 are all missense situated in the
KELCH domains 3 and 4 of the protein. Different models of patho-
genicity are proposed to explain variable transmission modes: dominant
negative missense variant in the autosomal dominant form, combina-
tion of hypomorphic and loss-of-function variants in the recessive form.
LZTR1 is a new player in the field of NS. Contrary to the other NS
genes, the functional link between LZTR1 and the RAS/MAPK pathway
remains elusive, although its involvement in schwannomatosis and its
cooperation with LOF in NF2 in the molecular pathogenesis of
schwannomas point to a converging action. One adult patient with a
dominant form developed “neuromas” on the right hand and forearm,
and a lipoma on the thorax. Another family with a recessive form (fa-
mily 1 in (Johnston et al., 2018)) showed subtle imaging compatible
with schwannomas in heterozygous carriers. Interestingly, a NS patient
presenting with schwannomatosis has been reported with a mutation in
KRAS (Bertola et al., 2012). We report here a patient with dominant
LZTR1-linked NS and an oligoastrocytoma.
2. Clinical report
The patient was born at 37 weeks of gestation with a birth weight of
2300 g (3rd-10th percentile). Early developmental milestones were
normal. At the age of 7, he was seen in the genetic department for short
stature (height at −2.86 SD), orthopedic troubles (weakness of ankle
dorsiflexion and scoliotic attitude) and a maternal family history of
Charcot-Marie-Tooth (CMT) syndrome. On clinical exam, he had a
normal head circumference (+0.13 SD), impression of downslanting
palpebral fissures and hypertelorism, a round face, a wide neck and a
shawl scrotum: the clinical features were suggestive for Aarskog or
Noonan syndrome but causal genes were not known at that time. The
patient and his mother were shown to carry the common 1,7 Mb du-
plication of CMT1A. Evolution of CMT was slowly progressive, with
bilateral pes cavus and mild weakness in the four limbs. Cryptorchidism
was also present in infancy but resolved spontaneously. He followed
normal schooling, but required extra educative support, noteworthy
because of his manual dyspraxia and distal muscular weakness. The
Fig. 1. Histological aspect of the tumor at age 22.
A. H&E staining (400x) showing an astrocytoma component with a gemistocytic pattern. B. H&E staining (400x): oligodendrocyte component (nuclear roundness and
perinuclear halo). C. ATRX immunostaining (200x): partial loss of ATRX expression, confirming the presence of a low grade astrocytoma component D. IDH-1
immunostaining (200x): IDH-1 expression in the low grade astrocytoma component E. IDH-1 immunostaining (200x): IDH-1 expression in the oligodendrocyte
component.
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patient was lost to follow up for more than a decade. Short stature was
treated with growth hormone between the age of 152/12 and 175/12
(0.033–0.037 mg/kg/day). At puberty, a rapidly progressive thoracic
kyphosis (radius 98°) with scoliosis (radius 37°) and lumbar scoliosis
developed that required braces for a couple of years. At the age of 22
years, the patient had several episodes of partial complex seizures. MRI
identified a right fronto-temporo-insular tumor encompassing the ar-
teria cerebri media. The tumor was surgically removed, followed by
radiotherapy. The patient was seen again in genetics at that time. He
was 154,5 cm tall (−3,05 SD), weighted 43.3 kg (BMI: 18.4) and had
an OFC of 57 cm (+0.16 SD). He had typical NS dysmorphism (trian-
gular face, hypertelorism, ptosis, thick lips with marked philtrum, ret-
rognathia, low set ears and thick helices), a severe kyphoscoliosis with a
gibbus, pectus excavatum, and generalized amyotrophy, more marked
in the calves. Neurologic examination showed generalized areflexia
compatible with CMT. He had no cardiac malformation, no cardio-
myopathy, and no hyperkeratosis. Coagulation screen showed a mild
defect in factor XI (44%), with normal INR and activated partial
thromboplastin time. At the age of 26, the patient presented several
new episodes of seizures. Brain MRI detected recurrence of the tumor.
The tumor did not respond to chemotherapy with temozolomide fol-
lowed by PCV (procarbazine, lomustine, vincristine). An attempt to
surgically resect the tumor failed and the patient died.
Neuropathological examination of the tumor at the time of the first
surgery showed grade II-III oligoastrocytoma with a gemistocytic
component (Fig. 1). Most cells showed a heterogeneous GFAP im-
munostaining, nuclear immunostaining for IDH1, SOX2 and P53, dif-
fuse membrane immunostaining for EGFR. Proliferative index using Ki-
67 was 3–4%. By FISH, the lesion showed 19q13 deletion, trisomy 7,
but no monosomy 10 and no deletion 1p36. Methylation of MGMT
promoter was normal. Neuropathological examination of the relapsing
tumor was now grade IV glioblastoma (Fig. 2). ATRX expression was
lost in most tumoral cells suggesting an ATRX mutation. GFAP im-
munostaining confirmed the astrocytic component of the tumor as well
as the presence of an associated oligodendroglial component. IDH-1
expression was homogeneous. Proliferative index using Ki-67 was
80–90%. Microarray showed no co-deletion 1p/19q and no 22q11 de-
letion. The p.Arg132His variant in IDH1 was detected, in keeping with a
secondary glioblastoma. The MGMT promoter was methylated.
Genetic screening using a large NGS panel of RASopathy genes
identified only a heterozygous variant in LZTR1(NM_006767.3):
c.850C > T (p.(Arg284Cys)). Analysis of lymphocyte RNA by RT PCR
in the proband using standard protocol failed to show aberrantly
spliced mRNAs The mutation was inherited from the mother who pre-
sented with mild dysmorphic features (ptosis, low-set ears) and ky-
phoscoliosis, but was not diagnosed as NS in infancy. As an adult, she
was 157.5 cm tall (−0.86 SD) and her head circumference was 56.4 cm
(+1.23 SD). Except for symptoms related to CMT1A, she did not have
any other significant health problems.
3. Discussion
We report a child with NS due to a LZTR1 variant. His c.850C > T
variant falls in the KELCH domain in which are observed the dominant
variations of LZTR1 (Johnston et al., 2018). We confirmed that re-
cessive inheritance was unlikely in this patient: no other variant was
identified despite full coverage of the coding sequence, and no splice
variant could be detected by RT-PCR. Moreover, no other mutation in
Fig. 2. Histological aspect of the tumor at age 26.
A. H&E staining (200x) showing a highly cellular tumor with features of microvascular proliferation and hyperplastic endothelial cellsB.IDH-1 immunostaining
(200x): diffuse nuclear and cytoplasmic IDH-1 expression. C. ATRX immunostaining (150x): diffuse loss of ATRX expression in accordance with the diagnosis of
secondary glioblastoma. D.KI-67 immunostaining (100x): high proliferative index (80–90%).
A. Jacquinet, et al. European Journal of Medical Genetics 63 (2020) 103617
3
known or suspected NS genes was detected. p.(Arg284Cys) has pre-
viously been reported in two instances. This variant was reported as
sporadic in a 42-year-old patient with inguinal and spinal schwanno-
matosis. Her phenotype was not otherwise described, (patient 388 in
(Paganini et al., 2015)). It was also observed in a NS family. The seg-
regation of the variant was compatible with dominant inheritance.
Affected subjects had no benign or malignant tumor (Yamamoto et al.,
2015). Somatic mutation in that amino acid location were also identi-
fied in malignant tumor samples (p.Arg284Cys in intestinal adeno-
carcinoma and endometrioid carcinoma; p.Arg284Ser in an astro-
cytoma grade IV and p.Arg284His in an intestinal adenocarcinoma)
(COSMIC database, http://www.sanger.ac.uk/cosmic).
NS, as other RASopathies, is a cancer-prone disorder (Smpokou
et al., 2015). The cumulative risk of cancer in NS is evaluated at 4% at
age 20 (Jongmans et al., 2011; Kratz et al., 2011, 2015). LZTR1 variants
have been associated with acute lymphoblastic leukemia in 2 patients
(Johnston et al., 2018). Glial tumors of the central nervous system are a
well-known complication of RASopathies. The most common form is
the low-grade, usually indolent pilocytic astrocytoma of the optic
pathway observed in NF1, but there have been multiple reports of NF1
patients with more aggressive CNS lesions: anaplastic medulloblastoma,
astrocytoma, oligodendroglioma, high grade glioma (Byrne et al., 2017;
Rosenfeld et al., 2010). A recent review identified 22 case reports of NS
with brain tumors, mainly dysembryoplasic neuroepithelial tumors
(DNET), but also medulloblastomas, oligodendrogliomas, astrocytomas,
pilocytic astrocytomas, gliomas and mixed glioneuronal tumors
(McWilliams et al., 2016). Two other patients were subsequently re-
ported (Bangalore Krishna et al., 2017). An uncharacterized brain
tumor was reported in one NRAS-related NS (Altmüller et al., 2017).
In our patient, based on histological findings, cerebral biopsy at
diagnosis was compatible with oligo-astrocytoma, a mixed glioma
tumor containing both abnormal oligodendroglial and astrocytic cells.
The recurrence of the tumor was in the form of a glioblastoma, the most
malignant and rapidly growing type of diffuse astrocytoma (WHO grade
IV). The presence of IDH-1 mutation (p.Arg132His being the most fre-
quent) differentiates secondary glioblastoma (IDH-1 mutant glio-
blastoma following the WHO 2016 classification (Louis et al., 2016;
Wesseling and Capper, 2018)) from the much more frequent primary
glioblastoma (IDH-1 wildtype glioblastoma). In our patient, the mole-
cular signature for the relapsing tumor (IDH-mutant, 1p/19q non-co-
deleted) with loss of ATRX expression confirms that the secondary
glioblastoma originated from the astrocytic component of the precursor
tumor (Reuss et al., 2015). No Noonan patient with LOF mutation in
LZTR1 has been reported with glioblastoma, meningioma, or any other
malignant CNS tumor so far. Although published evidences seem to
split LOF mutations responsible of a peripheral nerve disorder that do
not present as a RASopathy from another mechanism of mutations that
causes NS, the observation of at least one affected NS patient showing
schwannomas may indicate a more complex physiopathology and a role
of LZTR1 mutations in the development of both benign and malignant
neuroglial tumors in the central and the peripheral nervous system.
Although GH treatment is generally considered safe in patients with
no previous history of cancer (Pekic et al., 2017; Swerdlow et al., 2017),
promotion of tumor by GH treatment remains a debated issue in the
field of RASopathies. At this point, no clear conclusion can be drawn
from the literature, but the increase in tumoral risk has generally been
felt to be minimal. In their review on CNS tumors and NS, the authors
raised a possible relation with growth hormone treatment (McWilliams
et al., 2016). Indication of systematic MRI prior to GH treatment has
been discussed (Bangalore Krishna et al., 2017).
Whether LZTR1-related NS convey a higher risk of CNS tumors than
other NS forms cannot be drawn from a single case report. Nevertheless,
involvement of this gene as driver in glioblastoma, and its implication
in benign nerve sheet tumors may suggest that tumoral occurrence is
not fortuitous.
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